Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) – Equities researchers at William Blair raised their FY2018 earnings per share estimates for Allscripts Healthcare Solutions in a note issued to investors on Monday. William Blair analyst J. Garro now expects that the software maker will earn $0.72 per share for the year, up from their previous forecast of $0.57.

Other analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Tuesday, November 7th. SunTrust Banks reissued a “buy” rating and issued a $16.00 price target on shares of Allscripts Healthcare Solutions in a research note on Friday, November 3rd. Maxim Group reissued a “buy” rating and issued a $16.00 price target on shares of Allscripts Healthcare Solutions in a research note on Friday, November 3rd. Royal Bank of Canada set a $19.00 price target on shares of Allscripts Healthcare Solutions and gave the stock a “buy” rating in a research note on Thursday, January 11th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 price target on shares of Allscripts Healthcare Solutions in a research note on Monday, January 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $15.66.

Allscripts Healthcare Solutions (MDRX) traded up $0.04 during trading on Tuesday, hitting $14.95. 605,941 shares of the stock were exchanged, compared to its average volume of 1,585,517. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $2,730.09, a price-to-earnings ratio of -12.85, a P/E/G ratio of 2.13 and a beta of 1.33. Allscripts Healthcare Solutions has a one year low of $11.25 and a one year high of $16.13.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last posted its earnings results on Thursday, November 2nd. The software maker reported $0.12 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.12. The company had revenue of $451.20 million during the quarter, compared to analyst estimates of $429.94 million. Allscripts Healthcare Solutions had a negative net margin of 12.23% and a positive return on equity of 6.53%.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Quantitative Systematic Strategies LLC bought a new position in shares of Allscripts Healthcare Solutions during the fourth quarter valued at approximately $182,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Allscripts Healthcare Solutions by 27.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,584 shares of the software maker’s stock valued at $678,000 after purchasing an additional 9,957 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in shares of Allscripts Healthcare Solutions by 2.7% during the fourth quarter. Mutual of America Capital Management LLC now owns 150,166 shares of the software maker’s stock valued at $2,185,000 after purchasing an additional 3,989 shares in the last quarter. Cigna Investments Inc. New bought a new position in shares of Allscripts Healthcare Solutions during the fourth quarter valued at approximately $259,000. Finally, Community Trust & Investment Co. bought a new position in shares of Allscripts Healthcare Solutions during the fourth quarter valued at approximately $8,693,000.

In other Allscripts Healthcare Solutions news, President Richard J. Poulton sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $14.26, for a total transaction of $213,900.00. Following the completion of the transaction, the president now owns 1,351,773 shares of the company’s stock, valued at $19,276,282.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP James Hewitt sold 36,796 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $14.11, for a total transaction of $519,191.56. Following the transaction, the senior vice president now directly owns 181,766 shares of the company’s stock, valued at approximately $2,564,718.26. The disclosure for this sale can be found here. Insiders have sold 56,796 shares of company stock valued at $804,842 in the last ninety days. Insiders own 0.75% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/02/01/fy2018-earnings-forecast-for-allscripts-healthcare-solutions-inc-mdrx-issued-by-william-blair.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.